2. Search Result
Search Result
Results for "

antidiabetic agent

" in MedChemExpress (MCE) Product Catalog:

64

Inhibitors & Agonists

3

Peptides

19

Natural
Products

4

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-109144
    Enavogliflozin

    DWP-16001

    		 SGLT Metabolic Disease
    Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor .
    Enavogliflozin
  • HY-B2099A
    Buformin hydrochloride
    3 Publications Verification

    1-Butylbiguanide hydrochloride

    		 AMPK Cancer
    Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .
    Buformin hydrochloride
  • HY-16397A
    Phenformin hydrochloride
    5+ Cited Publications

    Phenethylbiguanide hydrochloride

    		 AMPK Autophagy Cancer
    Phenformin hydrochloride is an anti-diabetic agent from the biguanide class, can activate AMPK activity.
    Phenformin hydrochloride
  • HY-161429
    Antidiabetic agent 5

    		Amylases Glucosidase Metabolic Disease
    Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and α-amylase with IC50 values of 3.91, 8.89 µM, respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes .
    Antidiabetic agent 5
  • HY-163853
    Antidiabetic agent 6

    		GLUT Akt Metabolic Disease
    Antidiabetic agent 6 (Compound 19) is an antidiabetic Agent. Antidiabetic agent 6 stimulates GLUT4 translocation by activation of the PI3K/AKT-dependent signaling pathway. Antidiabetic agent 6 reduces blood glucose levels in Streptozotocin (HY-13753)-induced diabetic rats .
    Antidiabetic agent 6
  • HY-155961
    Antidiabetic agent 2

    		Dipeptidyl Peptidase Phosphatase Amylases Glucosidase Metabolic Disease
    Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC50s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels .
    Antidiabetic agent 2
  • HY-B2099
    Buformin

    1-Butylbiguanide

    		 AMPK Metabolic Disease Cancer
    Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .
    Buformin
  • HY-121731
    Nimbocinone

    		Others Metabolic Disease
    Nimbocinone, isolated from Azadirachta indica, exhibits antidiabetogenic activity .
    Nimbocinone
  • HY-101758
    BM-131246

    		Others Metabolic Disease
    BM-131246 is an oral antidiabetic agent.
    BM-131246
  • HY-120401
    Glybuzole

    Desaglybuzole

    		 Others Metabolic Disease
    Glybuzole (Desaglybuzole) is an orally active hypoglycaemic agent that has antidiabetic effect .
    Glybuzole
  • HY-P0058
    Pramlintide

    		Amylin Receptor Metabolic Disease Cancer
    Pramlintide is a polypeptide analogue of human amylin. Pramlintide, an antidiabetic agent, is antineoplastic in colorectal cancer .
    Pramlintide
  • HY-P0058B
    Pramlintide acetate

    		Amylin Receptor Metabolic Disease Cancer
    Pramlintide acetate is a polypeptide analogue of human amylin. Pramlintide acetate, an antidiabetic agent, is antineoplastic in colorectal cancer .
    Pramlintide acetate
  • HY-15516
    Sotagliflozin
    Maximum Cited Publications
    11 Publications Verification

    LX-4211; LP-802034

    		 SGLT Metabolic Disease
    Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.
    Sotagliflozin
  • HY-17451
    Glibornuride

    		Potassium Channel Metabolic Disease
    Glibornuride is a blocker of ATP-sensitive K + channels (KATP channel) with a pKi of 5.75 . Antidiabetic agent .
    Glibornuride
  • HY-P0058A
    Pramlintide TFA

    		Amylin Receptor Metabolic Disease Cancer
    Pramlintide TFA is a polypeptide analogue of human amylin. Pramlintide TFA, an antidiabetic agent, is antineoplastic in colorectal cancer .
    Pramlintide TFA
  • HY-W041324
    Glimepiride sulfonamide

    		Others Infection
    Glimepiride sulfonamide is a intermediate, and can be used to synthesize Glimepiride (HY-B0104) (antidiabetic agent) .
    Glimepiride sulfonamide
  • HY-B1114
    Gliquidone

    AR-DF 26

    		 Others Metabolic Disease
    Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.
    Gliquidone
  • HY-16397AS
    Phenformin-d5 hydrochloride

    Phenethylbiguanide-d5 hydrochloride

    		 Isotope-Labeled Compounds AMPK Autophagy Cancer
    Phenformin-d5 (hydrochloride) is the deuterium labeled Phenformin hydrochloride. Phenformin hydrochloride is an anti-diabetic agent from the biguanide class, can activate AMPK activity[1][2].
    Phenformin-d5 hydrochloride
  • HY-131504A
    Valienamine

    		Glucosidase Metabolic Disease
    Valienamine is the alpha-glucosidase inhibitor. Valienamine is the key functional component of many natural glycosidase inhibitors including the crop protectant validamycin A and the antidiabetic agent acarbose .
    Valienamine
  • HY-16397AR
    Phenformin hydrochloride (Standard)

    		AMPK Autophagy Cancer
    Phenformin (hydrochloride) (Standard) is the analytical standard of Phenformin (hydrochloride). This product is intended for research and analytical applications. Phenformin hydrochloride is an anti-diabetic agent from the biguanide class, can activate AMPK activity.
    Phenformin hydrochloride (Standard)
  • HY-B1114S
    Gliquidone-d6

    AR-DF 26-d6

    		 Isotope-Labeled Compounds Metabolic Disease
    Gliquidone-d6 is deuterium labeled Gliquidone. Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.
    Gliquidone-d6
  • HY-126198
    Linogliride

    McN-3935

    		 Antibiotic Metabolic Disease
    Linogliride (MCN-3935) is an antidiabetic agent. Linogliride (100 μM) does not affect insulin secretion in the absence of glucose, but has a significant insulinotropic effect in the presence of 5.5 mM glucose .
    Linogliride
  • HY-126198A
    Linogliride fumarate

    McN-3935 fumarate

    		 Antibiotic Metabolic Disease
    Linogliride (MCN-3935) fumarate is an antidiabetic agent. Linogliride fumarate (100 μM) does not affect insulin secretion in the absence of glucose, but has a significant insulinotropic effect in the presence of 5.5 mM glucose .
    Linogliride fumarate
  • HY-17451R
    Glibornuride (Standard)

    		Potassium Channel Metabolic Disease
    Glibornuride (Standard) is the analytical standard of Glibornuride. This product is intended for research and analytical applications. Glibornuride is a blocker of ATP-sensitive K+ channels (KATP channel) with a pKi of 5.75 . Antidiabetic agent .
    Glibornuride (Standard)
  • HY-115978
    α-Glucosidase-IN-2

    		Glucosidase Metabolic Disease
    α-Glucosidase-IN-2 (compound 5d) is a potent α-Glucosidase inhibitor with an IC50 of 9.48 µM. α-Glucosidase-IN-2 is an antidiabetic agent .
    α-Glucosidase-IN-2
  • HY-B1114R
    Gliquidone (Standard)

    		Others Metabolic Disease
    Gliquidone (Standard) is the analytical standard of Gliquidone. This product is intended for research and analytical applications. Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.
    Gliquidone (Standard)
  • HY-161782
    α-Amylase-IN-7

    		Amylases Metabolic Disease
    α-Amylase-IN-7 (Compound 6e) is an inhibitor for α-Amylase with an IC50 of 40 μM. α-Amylase-IN-7 exhibits potential as an antidiabetic agent .
    α-Amylase-IN-7
  • HY-W041324R
    Glimepiride sulfonamide (Standard)

    		Others Infection
    Glimepiride sulfonamide (Standard) is the analytical standard of Glimepiride sulfonamide. This product is intended for research and analytical applications. Glimepiride sulfonamide is a intermediate, and can be used to synthesize Glimepiride (HY-B0104) (antidiabetic agent) .
    Glimepiride sulfonamide (Standard)
  • HY-N7912
    Pterosin A

    (2S)-Pterosin A

    		 Others Metabolic Disease
    Pterosin A is an orally active anti-diabetic agent. Pterosin A promotes glucose uptake, increases serum insulin, and improves hyperglycemia and glucose intolerance in diabetic mice. Pterosin A can be isolated from Pteridium aquilinum .
    Pterosin A
  • HY-130289
    (±)4-HDHA

    4-Hydroxy docosahexaenoic acid; (±)4-HDoHE

    		 PPAR Metabolic Disease Inflammation/Immunology
    (±)4-HDHA (4-Hydroxy docosahexaenoic acid) is an autoxidation product of Docosahexaenoic acid (HY-B2167) (DHA). (±)4-HDHA is a PPARγ agonist, antidiabetic and anti-inflammatory agent .
    (±)4-HDHA
  • HY-115940
    Aldose reductase-IN-2

    		Aldose Reductase Metabolic Disease
    Aldose reductase-IN-2 (Compound 5f) is a potent inhibitor of aldose reductase (AR). Aldose reductase-IN-2 has antioxidation capacity. Aldose reductase-IN-2 is a promising anti-diabetic complications agent .
    Aldose reductase-IN-2
  • HY-B0401A
    Tolbutamide sodium

    		Apoptosis Metabolic Disease
    Tolbutamide sodium is a potent and orally active antidiabetic agent. Tolbutamide sodium induces apoptosis in a Ca 2+ dependent manner in pancreatic β-cells. Tolbutamide sodium has the potential for the research of non-insulin-dependent diabetes mellitus .
    Tolbutamide sodium
  • HY-122083
    T2384

    		PPAR Metabolic Disease
    T2384 is a peroxisome proliferator-activated receptor γ (PPARγ) ligand. T2384 also is an orally active antidiabetic agent. T2384 reduces the fasting plasma glucose levels and plasma insulin levels .
    T2384
  • HY-125012
    MAP4K4-IN-3
    1 Publications Verification

    		 MAP4K Metabolic Disease
    MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay. Antidiabetic agent .
    MAP4K4-IN-3
  • HY-N2486
    Desoxyrhaponticin
    1 Publications Verification

    		 Fatty Acid Synthase (FASN) Apoptosis Cancer
    Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .
    Desoxyrhaponticin
  • HY-W012634
    Benzothiazole

    		Bacterial Infection Metabolic Disease Inflammation/Immunology Cancer
    Benzothiazole is a natural occurring heterocyclic nuclei. Benzothiazole nucleus possesses a number of biological activities such as anticancer, antimicrobial, antidiabetic, anti-inflammatory, antileishmanial, and antiviral. Furthermore, Benzothiazole nucleus can function as an efficacious β-amyloid imaging agent [1][2][3][4].
    Benzothiazole
  • HY-N2413
    Gomisin D

    		Others Metabolic Disease
    Gomisin D, a lignan compound isolated from Fructus Schisandra, is a potential antidiabetic and anti-Alzheimer’s agent. Gomisin D inhibits UDP-Glucuronosyltransferases activity and scavenges ABTS(+) radicals. Gomisin D is used as a quality marker of Shengmai San and shenqi Jiangtang Granule .
    Gomisin D
  • HY-163899
    (+)-Crinatusin A1

    		Phosphatase Metabolic Disease
    (+)-Crinatusin A1 (Compound (+)- 4) is a chalcone-monoterpene hybrid, which can be isolated from Cleistocalyx operculatus. (+)-Crinatusin A1 is an inhibitor for protein tyrosine phosphatase 1B (PTP1B) with IC50 of 0.9 μM. (+)-Crinatusin A1 exhibits potential as an antidiabetic agent .
    (+)-Crinatusin A1
  • HY-B0254
    Glipizide

    CP 28720; K 4024

    		 Potassium Channel Metabolic Disease
    Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .
    Glipizide
  • HY-14894
    Ipragliflozin
    5+ Cited Publications

    ASP1941

    		 SGLT Metabolic Disease
    Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .
    Ipragliflozin
  • HY-152158
    α-Glucosidase-IN-22

    		Glucosidase Metabolic Disease
    α-Glucosidase-IN-22 (compound 7i), a benzimidazole, is a potent α-glucosidase inhibitor with an IC50 of 0.64 μM. α-Glucosidase-IN-22 is a potent anti-diabetic agent and has the potential for type 2 diabetes mellitus (T2DM) research .
    α-Glucosidase-IN-22
  • HY-16397
    Phenformin
    5+ Cited Publications

    Phenethylbiguanide

    		 Mitochondrial Metabolism AMPK Apoptosis Metabolic Disease Cancer
    Phenformin (1-phenethylbiguanide) is an orally active antidiabetic and anticancer agent. Phenformin has an incidence of associated lactic acidosis. Phenformin acts through acting AMPK activation and blocking mTOR pathway. Phenformin is also a substrate of P-glycoprotein (P-gp), and an OXPHOS inhibitor. Phenformin induces cancer cell apoptosis .
    Phenformin
  • HY-N11844
    Quercetin 3-(6″-caffeoylsophoroside)

    		Amylases Metabolic Disease
    Quercetin 3-(6″-caffeoylsophoroside) is an orally active α-amylase inhibitor, with an IC50 of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research .
    Quercetin 3-(6″-caffeoylsophoroside)
  • HY-14621
    Zingerone
    4 Publications Verification

    Vanillylacetone; Gingerone

    		 NF-κB Metabolic Disease Inflammation/Immunology Cancer
    Zingerone (Vanillylacetone) is a nontoxic methoxyphenol isolated from Zingiber officinale, with potent anti-inflammatory, antidiabetic, antilipolytic, antidiarrhoeic, antispasmodic and anti-tumor properties . Zingerone alleviates oxidative stress and inflammation, down-regulates NF-κB mediated signaling pathways . Zingerone acts as an anti-mitotic agent, and inhibits the growth of neuroblastoma cells .
    Zingerone
  • HY-134769
    OPC-163493

    		Mitochondrial Metabolism Reactive Oxygen Species Cardiovascular Disease Metabolic Disease
    OPC-163493 is an orally active liver-targeted mitochondrial uncoupling agent. OPC-163493 reduces Δψ and mitochondrial ROS production. OPC-163493 has antidiabetic and cardiovascular beneficial effects. OPC-163493 lowers blood pressure, extends survival, and improves renal function in the rat model of stroke/hypertension .
    OPC-163493
  • HY-N12353
    Stevisalioside A

    		Phosphatase Metabolic Disease
    Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC50: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .
    Stevisalioside A
  • HY-N2486R
    Desoxyrhaponticin (Standard)

    		Fatty Acid Synthase (FASN) Apoptosis Cancer
    Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .
    Desoxyrhaponticin (Standard)
  • HY-W012634R
    Benzothiazole (Standard)

    		Bacterial Infection Metabolic Disease Inflammation/Immunology Cancer
    Benzothiazole (Standard) is the analytical standard of Benzothiazole. This product is intended for research and analytical applications. Benzothiazole is a natural occurring heterocyclic nuclei. Benzothiazole nucleus possesses a number of biological activities such as anticancer, antimicrobial, antidiabetic, anti-inflammatory, antileishmanial, and antiviral. Furthermore, Benzothiazole nucleus can function as an efficacious β-amyloid imaging agent .
    Benzothiazole (Standard)
  • HY-42680
    D-Tagatose

    D-(-)-Tagatose

    		 Endogenous Metabolite Metabolic Disease Cancer
    D-Tagatose (D-(-)-Tagatose) is a rare monosaccharide found in nature with prebiotic characteristics. D-Tagatose is as a substitute for sucrose and a low-calorie sweetener in foodstuffs such as gum, fruit juice, and beverages. D-Tagatose is also a potential antidiabetic agent for the research of type II diabetes and a prebiotic to help elevate beneficial bacteria in the colon, prevent colon cancer, and lower cholesterol .
    D-Tagatose
  • HY-N6883
    6-Methoxytricin

    		Aldose Reductase Metabolic Disease
    6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC50 values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent .
    6-Methoxytricin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: